𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Economic Evaluation of Ropinirole Prolonged Release for Treatment of Parkinson’s Disease in The Netherlands

✍ Scribed by Boven, Job F. M.; Novak, Annoesjka; Driessen, Maurice T.; Boersma, Cornelis; Boomsma, Maarten M.; Postma, Maarten J.

Book ID
121537134
Publisher
Springer International Publishing AG
Year
2014
Tongue
English
Weight
562 KB
Volume
31
Category
Article
ISSN
1170-229X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Early treatment benefits of ropinirole p
Early treatment benefits of ropinirole prolonged release in Parkinson's disease patients with motor fluctuations
✍ Bonnie P. Hersh; Nancy L. Earl; Robert A. Hauser; Mark Stacy 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 488 KB 👁 1 views

A correct balance between endocannabinoid and dopamine-dependent systems is believed to underlie physiological motor control. We measured the levels of the endocannabinoid anandamide in the cerebrospinal fluid of Parkinson's disease (PD) patients. Subjects were divided into three groups: newly diagn

PREPARED: Comparison of prolonged and im
PREPARED: Comparison of prolonged and immediate release ropinirole in advanced Parkinson's disease
✍ Fabrizio Stocchi; Luigi Giorgi; Brian Hunter; Anthony HV Schapira 📂 Article 📅 2011 🏛 John Wiley and Sons 🌐 English ⚖ 266 KB

## Abstract Background: PREPARED was a randomized, parallel‐group, double‐blind, multicenter study to evaluate the efficacy of adjunctive ropinirole prolonged release (PR) versus immediate release (IR) in patients with advanced Parkinson's disease (PD). Methods: Patients received once‐daily PR (2–2

An open-label conversion study of pramip
An open-label conversion study of pramipexole to ropinirole prolonged release in Parkinson's disease
✍ Kelly E. Lyons; Rajesh Pahwa 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

## Abstract Ropinirole prolonged release (PR) is a once daily oral dopamine agonist approved for the treatment of Parkinson's disease (PD). The goal of this 4 week, open‐label study was to determine the most effective conversion ratio with the fewest adverse effects (AEs) when switching from pramip